Related Experiment Videos
C-erbB-2 immunostaining in laryngeal cancer
T Krecicki1, M Jeleń, M Zalesska-Krecicka
1Department of Otolaryngology--Head and Neck Surgery, Medical University, Wrocław, Poland.
Acta Oto-Laryngologica
|June 25, 1999
Summary
Protooncogene c-erbB-2 (HER2) expression in laryngeal squamous cell carcinomas showed a borderline difference in cancer patients versus controls. HER2 expression did not correlate with patient prognosis, indicating it
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tumour progression involves genetic alterations in protooncogenes and tumour suppressor genes.
- Protooncogene c-erbB-2 (HER2) is implicated in squamous cell carcinoma tumorigenesis.
- Understanding HER2's role in laryngeal cancer is crucial for prognosis.
Purpose of the Study:
- To analyze c-erbB-2 oncoprotein expression in laryngeal squamous cell carcinomas.
- To investigate the relationship between c-erbB-2 expression and clinical outcomes.
- To determine the prognostic value of c-erbB-2 in laryngeal carcinoma.
Main Methods:
- Immunohistochemical analysis of c-erbB-2 oncoprotein expression.
- Study included 154 cases of laryngeal squamous cell carcinomas.
- Correlation analysis with clinical parameters and patient survival.
Main Results:
- A borderline statistically significant difference (p = 0.0470) in c-erbB-2 expression was observed between cancer patients and controls.
- No significant correlation found between c-erbB-2 expression and patient demographics (sex, age).
- No significant correlation found between c-erbB-2 expression and tumour characteristics (T stage, lymph node status, site, grade) or clinical outcome.
Conclusions:
- Immunohistological examination of c-erbB-2 on paraffin sections is not a valuable prognostic factor for laryngeal carcinoma.
- The role of c-erbB-2 in the progression of laryngeal squamous cell carcinoma requires further investigation.
- Current findings do not support the use of c-erbB-2 as a predictive biomarker in this cancer type.